In-111 Dtpa Solution label

In-111 Dtpa Solution

In-111 Dtpa Solution Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

In-111 DTPA is indicated for use in  radionuclide cisternography

History

There is currently no drug history available for this drug.

Other Information

In-111 DTPA is supplied as a sterile, pyrogen-free, isotonic, aqueous solution that is  buffered to pH 7 to 8. At calibration time, each milliliter contains 2.5 mCi of Pentetate Indium Disodium In-111 (no carrier-added) and sodium bicarbonate for pH adjustment.

In-111 Dtpa Solution Manufacturers

  • In-111 Dtpa Solution | Anazaohealth Corporation
    No Recall

    In-111 Dtpa Solution | Anazaohealth Corporation

    In-111 Dtpa Solution | Anazaohealth Corporation

    Extreme care must be exercised to assure aseptic conditions in intrathecal injections. The maximum recommended intrathecal dose in the average patient (70kg) is 18.5 megabecquerels (500 microcuries). The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug preparations should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

    Storage and Handling

    Store vial in its lead shield at a temperature of 5-30º C. Do not freeze